citybiz – Questions & Answers with Sean A. MacDonald, Chief Executive Officer at Kainova Therapeutics
Article Date
January 15, 2026
This article is featured on another website.
Go to article
February 10, 2026
Kainova Therapeutics secures $CAD 32 million to accelerate the development of its immuno-oncology and inflammation portfolio.
February 10, 2026
Kainova Therapeutics secures $CAD 32 million to accelerate the development of its immuno-oncology and inflammation portfolio.
January 28, 2026
Why Australia & New Zealand Are Smart Alternatives for Your Clinical Trial During FDA Uncertainty
Navigating the Next Few Years with Confidence 2025 has been marked by significant regulatory…
January 28, 2026
Why Australia & New Zealand Are Smart Alternatives for Your Clinical Trial During FDA Uncertainty
Navigating the Next Few Years with Confidence 2025 has been marked by significant regulatory…